Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
Portfolio Pulse from
Acadia Pharmaceuticals has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $150 million. A portion of the proceeds will be paid to Neuren Pharmaceuticals as per a license agreement.
December 11, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acadia Pharmaceuticals has successfully sold its Rare Pediatric Disease Priority Review Voucher for $150 million. The company will share a portion of the proceeds with Neuren Pharmaceuticals as per their agreement.
The sale of the PRV for $150 million provides Acadia with significant capital, which could be used for further investments or operations. This is a positive financial event for the company, likely to have a favorable impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100